Glibenclamide

格列本脲

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameGlibenclamide
Drug Alias NameGlybenclamide优降糖格列苯脲Glyburide格列本尿 +[23] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionSulfonylurea receptor 1 inhibitors
TargetsSulfonylurea receptor 1
Therapy Area/IndicationsBrain metastasesDiabetes Mellitus, Type 2Diabetes Mellitus +[9] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryJapan
Original Approved Date1971/10/01
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer IncRemedy Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMilitary Medical Institute Academy of Military Sciences PLA ChinaRemedy Pharmaceuticals IncEton Pharmaceuticals Inc +[9] 
Inactive CompaniesGenuine Research Center, EgyptIqvia Rds (Shanghai) Co LtdWashington University School Of Medicine +[8] 
Active IndicationsDiabetes Mellitus, Type 2Diabetes MellitusNeuralgia +[5] 
Inactive IndicationsBrain metastasesStrokeBrain Contusion +[4] 

Other Information

ATC CodeA10BB01
Related LinksWikipediaDrugBankKEGG